Biorepository for cerebrovascular diseases in Florida
Creating a Florida Cerebrovascular Disease Biorepository and Genomics Center
This study is collecting medical histories and blood samples from people with cerebrovascular diseases in Florida to help researchers learn more about these conditions and find better treatments.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Mayo Clinic Academic / other |
| Locations | 1 site (Jacksonville, Florida) |
| Trial ID | NCT05491980 on ClinicalTrials.gov |
What this trial studies
This initiative aims to establish a comprehensive biorepository and resource center dedicated to cerebrovascular diseases across Florida. It involves collecting medical histories and blood samples from individuals affected by various cerebrovascular conditions, including ischemic stroke and aneurysmal subarachnoid hemorrhage. The collected data and samples will be utilized for future research aimed at understanding, preventing, and treating cerebrovascular diseases and related health issues.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with a range of cerebrovascular conditions such as ischemic stroke, transient ischemic attack, and intracerebral hemorrhage.
Not a fit: Patients with active or latent infections caused by virulent microorganisms will not benefit from this study.
Why it matters
Potential benefit: If successful, this biorepository could enhance research efforts leading to improved prevention and treatment strategies for cerebrovascular diseases.
How similar studies have performed: Other biorepositories focused on cerebrovascular diseases have shown promise in advancing research, indicating that this approach is both valuable and tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: • Affected subjects with diverse cerebrovascular conditions, including, but not limited to, ischemic stroke, transient ischemic attack (TIA), intracerebral hemorrhage (ICH), aneurysmal subarachnoid hemorrhage (aSAH), vascular dementia (VAD), anoxic brain injury, unruptured intracranial aneurysm (UIA), cavernous malformation, arteriovenous malformations (AVM), carotid and vertebral arterial dissections, symptomatic and asymptomatic cervical carotid artery atherosclerotic stenosis, non-aneurysmal perimesencephalic subarachnoid hemorrhage (naSAH), cerebral venous thrombosis (CVT), moyamoya disease, fibrosmuscular dysplasia (FMD), non-traumatic, angiography-negative subarachnoid hemorrhage, leukoaraiosis, arteriovenous fistula, reversible cerebral vasoconstriction syndrome (RCVS), and CADASIL. Exclusion Criteria: • All patients with the following known or suspected virulent microorganisms causing an active or latent infection will be excluded from the study: * Human immunodeficiency virus (HIV); * Any viral hepatitis; * West Nile virus (WNV); * Influenza virus; * Tuberculosis (TB); * Any bacteremia; * Any fungemia; * Any prionopathy.
Where this trial is running
Jacksonville, Florida
- Mayo Clinic Florida — Jacksonville, Florida, United States (Recruiting)
Study contacts
- Principal investigator: James Meschia, MD — Mayo Clinic
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.